Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 50,05 € (+16,88 %). La mediana es de 50,50 € (+17,94 %).
| Comprar |
5 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
HeartFlow: plaque analysis becomes main growth driver
HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » Más en de.investing.com
Heartflow climbs to new record high of $51.26
Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » Más en de.investing.com
Heartflow hits record high of $48.70 after strong Q2 results
Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » Más en de.investing.com
HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours
HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » Más en de.investing.com
HeartFlow beats Q1 forecasts, raises full-year outlook — shares slightly weaker
HeartFlow reported Q1 2026 EPS of -$0.16, beating the expected -$0.22; revenue rose 41% to $52.6 million. Non-GAAP gross margin improved to 80.5% and the non-GAAP net loss narrowed to $13.3 million. The company received positive feedback on new products such as the PCI Navigator and raised its 2026 revenue guidance to $228–232 million. Despite the results, the stock slipped 0.61% in after-hours trading. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 64,32 M | 63,12 % |
| Beneficio bruto | 53,78 M | 78,21 % |
| Beneficio neto | -10,16 M | 76,56 % |
| EBITDA | -10,13 M | 73,74 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 3730,23 M € |
Número de acciones | 87,89 M |
Máximo/mínimo de 52 semanas | 55,20 € - 18,32 € |
| Dividendos | No |
Beta | 2,02 |
Ratio P/E | -50,70 |
Ratio PEG | -0,81 |
Ratio P/B | 14,40 |
Ratio P/S | 17,18 |
Perfil de la empresa
HeartFlow, Inc., una empresa de tecnología médica, ofrece soluciones no invasivas para el diagnóstico y el manejo de las enfermedades de las arterias coronarias en todo el mundo. Su plataforma HeartFlow utiliza IA y dinámica de fluidos computacional para crear un modelo tridimensional personalizado del corazón de un paciente a partir de una única angiografía coronaria por tomografía computarizada, un tipo especializado de estudio que proporciona imágenes detalladas de las arterias del corazón. La plataforma de la empresa ofrece información sobre el flujo sanguíneo, la estenosis y el volumen y la composición de la placa, superando las limitaciones de las pruebas de imagen no invasivas tradicionales. La empresa fue fundada en 2007 y tiene su sede en Mountain View, California.
| Nombre | HeartFlow |
| CEO | John Farquhar |
| Sitio web | |
| Salida a bolsa | 07/08/2025 |
| Empleados | 843 |